May 14, 2026
China’s Pharmaceutical Weapon
This article was originally published in The National Interest.
This week’s Donald Trump–Xi Jinping summit in Beijing will not lack for contested business. Iran, Taiwan, AI, tariffs, and critical minerals will each compete for time on the agenda, and each will dominate the post-summit coverage. One item less likely to get airtime, however, is one with a direct impact on American lives: the dependence of the US pharmaceutical and biotechnology sector on Chinese inputs, and the leverage that dependence already hands Beijing.
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil, every dialysis shift in this country proceeds on the assumption that Beijing will not exercise leverage it already holds.
Heparin is the cleanest illustration. The drug is the blood thinner of record across American medicine—present in nearly every hemodialysis session, every major cardiac procedure, the standard treatment for deep-vein thrombosis and pulmonary embolism, and routine ICU protocols. Most of the US dialysis population—roughly 550,000 patients—have no clinical substitute available to them. The raw material is porcine intestinal mucosa, collected from thousands of small village workshops concentrated in China’s Shandong Province.
Read the full article in The National Interest.
More from CNAS
-
Video
Indo-Pacific Security / Energy, Economics & Security
Analysts Break Down Trump-Xi Meeting and Calls for Stability and CooperationFor perspective on President Trump's trip and the broader U.S.-China relationship, Geoff Bennett spoke with Myron Brilliant and Liza Tobin. Brilliant is at the DGA Group and i...
By Liza Tobin
-
Video
Indo-Pacific Security / Energy, Economics & Security
Rajdeep Sardesai Asks Big Question on US-ChinaThe debate on the Big Question, with Daniel Silverberg, adjunct senior fellow at the Center for a New American Security, explores whether Beijing holds the key to resolving th...
By Daniel Silverberg
-
The U.S. Is Losing Ground to China in Southeast Asia
Commentary
Without routine engagement, Southeast Asian countries become uneasy about U.S. commitments and tend to look elsewhere—such as to China—to fulfill their needs....
By Derek Grossman
-
Podcast
Indo-Pacific Security / Middle East Security
The Global Power Shift No One Is Talking About – And Who’s Driving ItMost people see the world as the U.S. vs. China. But the real power shift is happening elsewhere. Richard Fontaine, CEO of the Center for a New American Security and a former ...
By Richard Fontaine
